Literature DB >> 25553887

Acid suppression medications are associated with suboptimal weight loss after laparoscopic Roux-en-Y gastric bypass in patients older than 40 years.

Emily K Ward1, Elsbeth Jensen-Otsu2, Jonathon A Schoen3, Kevin Rothchild3, Breana Mitchell3, Gregory L Austin4.   

Abstract

BACKGROUND: Bariatric surgery, including laparoscopic Roux-en-Y gastric bypass (LRYGB), achieves the greatest long-term weight loss in severe obesity. Approximately 50%-60% of severely obese patients have gastroesophageal reflux disease, and a substantial proportion is taking a proton pump inhibitor (PPI) or histamine-2 blocker (H2 B) at the time of LRYGB. The objective of this study was to explore the association of PPI/H2 B use before LRYGB with suboptimal percent weight loss (PWL) after LRYGB.
METHODS: This was a cohort study of 472 consecutive patients who underwent LRYGB at a single center from 2004-2011. Suboptimal PWL was defined as<14% at 2 months,<25% at 6 months, and<30% at 12 months. Because of effect modification by age, stratified analyses (by median age of 40 yr) were performed. All models were adjusted for appropriate covariates, including obesity-associated co-morbidities.
RESULTS: For patients aged ≤40 years, PPI/H2 B use leading up to LRYGB was not associated with suboptimal PWL at 2 months (P = .86), 6 months (P = .47), or 12 months (P = .66). However, for patients aged>40 years, PPI/H2 B use leading up to LRYGB was associated with a nonsignificant increase in suboptimal PWL at 2 months (odds ratio [OR] 2.23; P = .08) and significant increases in suboptimal PWL at 6 months (OR 7.23; P = .002) and 12 months (OR 11.1; P = .02). Results were independent of GERD.
CONCLUSIONS: Mechanisms for the poorer weight loss in patients aged>40 years who were using a PPI/H2 B just before LRYGB should be explored.
Copyright © 2015 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gastroesophageal reflux disease; Histamine 2 blocker; Proton pump inhibitor; Roux-en-Y gastric bypass; Weight loss

Mesh:

Substances:

Year:  2014        PMID: 25553887     DOI: 10.1016/j.soard.2014.09.027

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  4 in total

1.  Response to letter to the editor Re: The effect of PPI use on human gut microbiota and weight loss in patients undergoing laparoscopic Roux-en-Y gastric bypass.

Authors:  Gregory L Austin; Emily K Ward
Journal:  Obes Surg       Date:  2015-06       Impact factor: 4.129

Review 2.  A comprehensive diagnostic approach to detect underlying causes of obesity in adults.

Authors:  Eline S van der Valk; Erica L T van den Akker; Mesut Savas; Lotte Kleinendorst; Jenny A Visser; Mieke M Van Haelst; Arya M Sharma; Elisabeth F C van Rossum
Journal:  Obes Rev       Date:  2019-03-01       Impact factor: 9.213

3.  Recommendations Based on Evidence by the Andalusian Group for Nutrition Reflection and Investigation (GARIN) for the Pre- and Postoperative Management of Patients Undergoing Obesity Surgery.

Authors:  Antonio J Martínez-Ortega; Gabriel Olveira; José L Pereira-Cunill; Carmen Arraiza-Irigoyen; José M García-Almeida; José A Irles Rocamora; María J Molina-Puerta; Juan B Molina Soria; Juana M Rabat-Restrepo; María I Rebollo-Pérez; María P Serrano-Aguayo; Carmen Tenorio-Jiménez; Francisco J Vílches-López; Pedro P García-Luna
Journal:  Nutrients       Date:  2020-07-06       Impact factor: 5.717

4.  Association of Proton Pump Inhibitor (PPI) Use with Energy Intake, Physical Activity, and Weight Gain.

Authors:  Jennifer L Czwornog; Gregory L Austin
Journal:  Nutrients       Date:  2015-10-19       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.